SIMS PETITION ON PMA PREEMPTION OF TORT CLAIMS COULD RECEIVE SUPREME COURT RULING IN EARLY JANUARY; FDA DRAFT RULE REITERATES NARROW INTERPRETATION
This article was originally published in The Gray Sheet
Executive Summary
The U.S. Supreme Court could announce as early as Jan. 12 whether to O.K. or deny a writ of certiorari for a case, Kernats v. Sims, that raises the issue of whether FDA's premarket approval application and investigational device exemption processes preempt state common law tort claims.
You may also be interested in...
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.